|
|
|
This bibliography is provided as a service to our readers. It is compiled from the entries in the BCERF Environmental Risk Factors Bibliographic Database.
This bibliography is arranged topically. The topics include:
Review Articles and Commentaries
Archer, D. F., Bush, T., and Nachtigall, L. E. (2000). Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 92, 1950-1952.
Avis, N. E., Crawford, S. L., and McKinlay, S. M. (1997). Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health 3, 103-120.
Barlow, D. H. (1997). HRT and the risk of deep vein thrombosis. International Journal of Gynecology & Obsterics 59, S29-S33.
Barrett-Connor, E. (1999). Postmenopausal estrogen therapy and selected (less-often-considered) disease outcomes. Menopause 6, 14-20.
Barrett-Connor, E., and Grady, D. (1998). Hormone replacement therapy, heart disease and other considerations. Annual Reviews of Public Health 19, 55-72.
Barrett-Connor, E., Wenger, N. K., Grady, D., Mosca, L., Collins, P., Kornitzer, M., Cox, D. A., Moscarelli, E., and Anderson, P. W. (1998). Coronary heart disease in women. Randomized clinical trials, HERS and RUTH. Maturitas 31, 1-7.
Beral, V., Banks, E., Reeves, G., and Appleby, P. (1999). Use of HRT and subsequent risk of cancer. Journal of Epidemiology and Biostatistics 4, 191-215.
Bernstein, L., and Ross, R. K. (1993). Endogenous hormones and breast cancer risk. Epidemiologic Reviews 15, 48-64.
Boroditsky, R. S. (2000). Balancing safety and efficacy focus on endometrial protection. The Journal of Reproductive Medicine 45, 273-284.
Braendle, W. (1998). Hormone replacement therapy in women with breast cancer. Anticancer Research 18, 2253-2256.
Bungay, G. T., Vessey, M. P., and McPherson, C. K. (1980). Study of symptoms in middle life with special reference to the menopause. British Medical Journal 281, 181-183.
Burger, H. G. (1999). The endocrinology of the menopause. Journal of Steroid Biochemistry and Molecular Biology 69, 31-35.
Bush, T. L. (2000). Preserving cardiovascular benefits of hormone replacement therapy. Journal of Reproductive Medicine 45, 259-273.
Castelli, W. P. (1999). Cardiovascular disease: pathogenesis, epidemiology, and the risk among users of oral contraceptives who smoke. American Journal of Obstetric Gynecology 180, S349-S356.
Chiechi, L. M. (1999). Dietary phytoestrogens in the prevention of long-term postmenopausal diseases. International Journal of Gynecology & Obstetrics 67, 39-40.
Chiechi, L. M., and Secreto, G. (2000). Factors of risk for breast cancer influencing post menopausal long-term hormone replacement therapy. Tumori 86, 12-16.
Chiechi, L. M., Lobascio, A., Grillo, A., and Valerio, T. (1999). Phytoestrogen-containing food and prevention of postmenopausal osteoporosis and cardiovascular diseases. Minerva Ginecologica 51, 343-348.
Chopra, A. (2000). Osteoporosis: a new understanding of its impact and pathogenesis. Journal of American Osteopathic Association 100, S1-S4.
Cohen, A. J., and Roe, F. J. C. (2000). Review of risk factors for osteoporosis with particular reference to a possible aetiological role of dietary salt. Food and Chemical Toxicology 38, 237-253.
Colditz, A. A. (1997). Estrogen Replacement therapy for breast cancer patients. Oncology 11, 1491-1497.
Colditz, G. (1999). Hormones and breast cancer: Evidence and implications for consideration of risk and benefits of hormone replacement therapy. Journal of Women's Health 8, 347-357.
Colditz, G. A. (1997). Hormone replacement therapy increases the risk of breast cancer. Annals of the New York Acadamy of Science 833, 129-136.
Colditz, G. A. (1998). Relationship between estrogen levels, use of hormone replacement therapy and breast cancer. Journal of the National Cancer Institute 90, 814-823.
Coope, J. (1996). Hormonal and non-hormonal interventions for menopausal symptoms. Maturitas 23, 159-168.
Crawford, S. L., Casey, V. A., Avis, N. E., and McKinlay, S. M. (2000). A longitudinal study of weight and the menopause transition: Results from the Massachusetts Women's Health Study. Menopause 7, 96-104.
Crawshaw, A. (2000). Carcinoma of the breast and hormone replacement therapy for osteoporosis. International Journal of Clinical Practice 54, 99-103.
Deligdisch, L. (1999). Hormonal Pathology of the Endometrium. Modern Pathology 13, 285-294.
Dennerstein, L. (1996). Well-being, symptoms and the menopausal transition. Maturitas 23, 147-157.
Disaia, P. J. (1997). Estrogen replacement therapy for the breast cancer survivor: A reappraisal. Journal of Surgical Onclolgy 64, 175-180.
Doering, W. V. E. (1996). Antioxidant vitamins, cancer, and cardiovascular disease. New England Journal of Medicine 335, 1165-1169.
Dorland, M., van Kooij, R. J., and te Velde, E. R. (1998). General ageing and ovarian ageing. Maturitas 30, 113-118.
Dowsett, M. (2000). Use of risk determinants for different breast cancer prevention strategies. European Journal of Cancer 36, 1283-1287.
Ducy, P., Schinks, T., and Karsenty, G. (2000). The osteoblast: A sophisticated fibroblast under central surveillance. Science 289, 1501-1504.
Dupont, W. D., and Page, D. L. (1991). Menopausal Estrogen Replacement Therapy and Breast Cancer. Arch Internal Medicine 151, 62-72.
Emans, S. J. (1997). Menarche and beyond--Do eating and exercise make a difference? Eating and Exercise 26, S137-S141.
ESHRE Capri Workshop Group (1998). Hormones and cardiovascular diseases: Oral contraceptives and hormonal replacement therapy: differential effects on coronary heart disease, deep venous thrombosis and stroke. Human Reproduction 13, 2325-2333.
Feigelson, H. S., and Henderson, B. E. (1996). Estrogens and breast cancer. Carcinogenesis 17, 2279-2284.
Felson, D. T., and Nevitt, M. C. (1999). Estrogen and osteoarthritis: How do we explain conflicting study results. Preventive Medicine 28, 445-448.
Fentiman, I. S. (2000). Future prospects for the prevention and cure of breast cancer. European Journal of Cancer 36, 1085-1088.
Fuchs, C. S., Stampfer, M. J., Colditz, G. A., Giovannucci, E. L., Manson, J. E., Kawachi, I., Hunter, D. J., Hankinson, S. E., Hennekens, C. H., Rosner, B., et al. (1995). Alcohol consumption and mortality among women. The New England Journal of Medicine 332, 1245-1250.
Gadducci, N., Fanucchi, A., Cosio, S., and Genazzani, A. R. (1997). Hormone replacement therapy and gynecological cancer. Anticancer Research 17, 3793-3998.
Gambrell, R. D., Maier, R. C., and Sanders, B. I. (1983). Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstetrics and Gynecology 62, 435-443.
Gottleib, N. (2000). Nonhormonal agents show promise against hot flashes. Journal of the National Cancer Institute 92, 1118-1120.
Grady, D., and Ernster, V. L. (1997). Hormone replacement therapy and endometrial cancer: Are current regimens safe? Journal of the National Cancer Institute 89, 1088-1089.
Grady, D., Rubin, S. M., Petitti, D. B., S., F. C., Black, D., Ettinger, B., Ernster, V. L., and Cummings, S. R. (1995). Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine 117, 1016-1037.
Greendale, G. A., Reboussin, B. A., Sie, A., Singh, H. R., Olson, L. K., Gatewood, O., Bassett, L. W., Wasilauskas, C., Bush, T., and Barrett-Connor, E. (1999). Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Annals of Internal Medicine 130, 262-269.
Gustafsson, J.-A. (2000). Novel Aspects of estrogen action. Journal of Society for Gynecologic Investigation 7, 8S-9S.
Hagstad, A., and Janson, P. O. (1986). The epidemiology of climacteric symptoms. Acta Obstetrica et Gynecologica Scandinavica Supplement 134, 59-65.
Helzlsouer, K. J. (1999). Bad News/ Good News: Information about breast cancer risk following prophylactic oophorectomy. Journal of the National Cancer Institute 91, 1442-1443.
Herrington, D. M. (1999). The HERS trial results: Paradigms lost? Annals of Internal Medicine 131, 463-466.
Hindle, W. H. (1999). Hormone alterations in breast cancer: examining the hypothesis. Medscape Womens Health 4, 4.
Hulka, B. S., and Brinton, L. A. (1995). Hormones and breast and endometrial cancers: Preventive strategies and future research. Environmental Health Perspectives 103, 185-189.
Hulley, S. (2000). Estrogens should not be initiated for the secondary prevention of coronary artery disease: A debate. Canadian Journal of Cardiology 16, 10E-12E.
Innes, K. E., and Byers, T. E. (1999). Preeclapsia and breast cancer risk. Epidemiology 10, 722-732.
Institute of Medicine, NAS. (1999). Dietary reference intake for calcium, phosphorus, magnesium, vitamin D, and fluoride. In Dietary Reference Intake (Washington, D. C., National Acadamy Press), pp. 83.
Jacobs, H. S. (2000). Hormone replacement therapy and breast cancer. Endocrine-related Cancer 7, 53-61.
Jasienska, G., Thune, I., and Ellison, P. T. (2000). Energetic factors, ovarian steroids and the risk of breast cancer. European Journal of Cancer Prevention 9, 231-239.
Jenkins, D., Kendall, C., Vidgen, E., Agarwal, S., Rao, A., Rosenberg, R., Diamandis, E., Novokmet, R., Mehling, C., Perera, T., et al. (1999). Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: A controlled crossover trial. American Journal of Clinical Nutrition 69, 395-402.
Johannes, C. B., and Crawford, S. L. (1999). Menstrual bleeding, hormones, and the menopausal transition. Seminars in Reproductive Endocrinology 17, 299-309.
Kaufert, P. A. (1996). The social and cultural context of menopause. Maturitas 23, 169-180.
Kester, M. H., Bulduk, S., Tibboel, D., Meinl, W., Glatt, H., Falany, C. N., Coughtrie, M. W., Key, T. J. (1999). Serum Oestradiol and breast Cancer risk. Endocrine-related Cancer 6, 175-180.
Kirkwood, T. B. L. (1998). Ovarian ageing and the general biology of senescence. Maturitas 30, 105-111.
Korach, K. S. (2000). Estrogen receptor knock-out mice: Molecular and endocrine phenotypes. Journal of Society for Gynocologic Investigation 7, S16-S17.
Kuller, L. H. (2000). Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 92, 1100-1101.
Kuller, L. H. (2000). Hormone replacement therapy and coronary heart disease. A new debate. Medical Clinics of North America 84, 181-198.
Lamberts, S. W. J., Beld, A. W. v. d., and der Lely, A.-J. v. (1997). The endocrinology of aging. Science 278, 419-424.
Lane, J. M., Russell, L., and Khan, S. N. (2000). Osteoporosis. Clinical Orthopometry 372, 139-150.
Leake, R. (1999). Contents of HRT and mechanisms of action. Journa; of Epidemiology and Biostatics 4, 129-139.
Leiter, L. A. (2000). Estrogens are indicated for the prevention of coronary artery disease: A debate for estrogen. Canadian Journal of Cardiology 16, 13E-16E.
Liehr, J. G. (1997). Dual role of oestrogens as hormones and pro-carcinogens: Tumour initiation by metabolic activation of oestrogens. European Journal of Cancer 6, 3-10.
Ludwig, D. S., Pereira, M. A., Kroenke, C. H., Hilner, J. E., Van Horn, L., Slattery, M. L., and Jacobs, D. R. (1999). Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. Journal of the American Medical Association 282, 1539-1546.
Masamura, S., Santner, S. J., Gimotty, P., George, J., and Santen, R. J. (1997). Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake. Breast Cancer Research and Treatment 42, 215-226.
McClung, M. R. (1999). Therapy for fracture prevention. Journal of the American Medical Association 282, 687-689.
McGowan, J. A., and Pottern, L. (2000). Commentary on the Women's Health Initiative. Maturitas 34, 109-112.
McKinlay, S. M. (1996). The normal menopause transition: an overview. Maturitas 23, 137-145.
McKinlay, S. M., and Jefferys, M. (1974). The menopausal syndrome. British Journal of Preventive and Social Medicine 28, 108-115.
McPherson, R. (2000). Is hormone replacement therapy cardioprotective? Decision-making after the heart and estrogen/progestin replacement study. Canadian Journal of Cardiology 16, 14A-19A.
Meade, T. W., and Vickers, M. R. (1999). HRT and cardiovascular disease. Journal of Epidemiology & Biostatistics 4, 165-190.
Moorman, P. G., Kuwabara, H., Millikan, R. C., and Newman, B. (2000). Menopausal Hormones and breast cancer in a biracial population. American Journal of Public Health 90, 966-971.
Mosca, L., Collins, P., Herrington, D. M., Mendelsohn, M. E., Paternak, R. C., Robertson, R. M., Schenck-Gustafsson, K., Smith, S. C., Taubert, K. A., and Wegner, N. K. (2001). Hormone replacement therapy and cardiovascular Disease: A Statement for healthcare professionals from the American Heart Association. Circulation 104, 499-503.
Muttukrishna, S., Child, T., Lockwood, G. M., Groome, N. P., Barlow, D. H., and Ledger, W. L. (2000). Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women. Human Reproduction 15, 549-556.
Nawaz, H., and Katz, D. L. (1999). American College of Preventive Medicine practice policy statement. American Journal of Preventive Medicine 17, 250-254.
Norman, A. W., and Litwack, G. (1997). Estrogens and Progestins. In Hormones (New York, Academic Press), pp. 361-386.
Oparil, S. (1999). Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection. Hypertension 33, 170-176.
Panico, S., Galasso, R., Celentano, E., Ciadullo, A. V., Frova, L., Capocaccia, R., Trevisan, M., and Berriino, F. (2000). Large-scale hormone replacement therapy and life expectancy:results from an international comparison European and North American populations. American Journal of Public Health 90, 1397-1402.
Pathak, D. R., Osuch, J. R., and He, J. (2000). Breast Carcinoma Etiology. Cancer 88, 1230-1238.
Persson, I. (2000). Estrogens in the causation of breast, endometrial and ovarian cancers - Evidence and hypotheses from epidemiological findings. Journal of Steroid Biochemistry and Molecular Biology 74, 357-364.
Pfeilschifter, J., and Diel, I. J. (2000). Osteoporosis due to cancer treatment: pathogenesis and management. Journal of Clinical Oncology 18, 1570-1593.
Pickar, J. H., Thorneycroft, I., and Whitehead, M. (1998). Effects of hormone replacement therapy on the endometrium and lipid parameters: A review of randomized clinical trials, 1985 to 1995. American Journal of Obsterics and Gynecology 178, 1087-1098.
Pines, A. (2000). Postmenopausal hormone therapy and coronary heart disease-clinical implications of recent randomized trial results. Maturitas 35, 99-105.
Ravn, S. H., Rosenberg, J., and Bostofte, E. (1994). Postmenopausal hormone replacement therapy -- clinical implications. European Journal of Obstetrics, Gynecology and Reproduction Biology 53, 81-93.
Rodan, G. A., and Martin, T. J. (2000). Therapeutic Approaches to Bone Diseases. Science 289, 1508-1514.
Rose, S., and Maffulli, N. (1999). Hip Fractures. An epidemiological review. Bulletin of the Hospital for Joint Diseases 58, 197-201.
Rosenberg, C. R., Pasternack, B. S., Shore, R. E., Koenig, K. L., and Toniolo, P. G. (1994). Pregenopausal Estradiol levels and the risk of breast cancer: A new method of controlling for day of the menstrual cycle. American Journal of Epidemiology 140, 518-524.
Ross, P. D. (1996). Osteoporosis, Frequency, consequences and risk factors. Archives of Internal Medicine 156, 1399-13411.
Ross, R. K., Paganini_Hill, A., Wan, P. C., and Pike, M. C. (2000). Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 92, 328-332.
Santen, R. J., and Petroni, G. R. (1999). Relative versus attributable risk of breast cancer from estrogen replacement therapy. Journal of Clinical Endocrinology & Metabolism 84, 1875-1880.
Schairer, C., Lubin, J., Troisi, R., Sturgeon, S., Brinton, L., and Hoover, R. (2000). Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. Journal of the American Medical Association 283, 485-491.
Shaywitz, B. A., and Shaywitz, S. E. (2000). Estrogen and Alzheimer disease: plausible theory, negative clinical trial. Journal of American Medical Association 283, 1055-1056.
Sillero-Arenas, M., Delgado-Rodriquez, R., R., R.-C., Bueno-Cavanillas, A., and Galvez-Vargas, R. (1992). Menopausal hormones. Obsterics and Gynecology 79, 286-294.
Speroff, L. (1999). Postmenopausal hormone therapy and the risk of breast cancer. Maturitas 32, 123-129.
Spicer, D. V., Krecker, E. A., and Pike, M. C. (1995). The endocrine prevention of breast cancer. Cancer Investigations 13, 495-504.
Stearns, V., Isaacs, C., Rowland, J., Crawford, J., Ellis, M. J., Kramer, R., Lawrence, W., Hanfelt, J. J., and Hayes, D. F. (2000). A pilot trial assessing the efficacy of paroxetine hydrochloride (paxil) in controling hot flashes in breast cancer survivors. Annals of Oncology 11, 17-22.
te Velde, E. R., Dorland, M., and Broekmans, F. J. (1998). Age at menopause as a marker of reproduction. Maturitas 30, 119-125.
Teitalbaum, S. L. (2000). Bone resorption by osteoclasts. Science 289, 1504-1505.
Thijssen, J. H. H. (1997). Oestrogens, progestins and breast proliferation. Zentralblatt fur Gynakologie 119, 43-47.
Uhler, M. L., Marks, J. W., and Judd, H. L. (2000). Estrogen replacement therapy and gallbladder disease in postmenopausal women. Menopause 7, 162-167.
Ursin, G., Li, C., and Pike, M. C. (2000). Should women with a family history of breast cancer avoid use of oral contraceptives? Epidemiology 11, 615-616.
Verheul, H. A. M., Coelingh-Bennink, H. J. T., Kenemans, P., Atsma, W. J., Burger, C. W., Eden, J. A., Hammer, M., Marsden, J., and Purdie, D. W. (2000). Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas 36, 1-17.
Vihko, R. K., and Apter, D. L. (1986). The epidemiology and endocrinology of the menarche in relation to breast cancer. Cancer Surveys 5, 561-571.
Walker, R. A. (1999). Oestrogen receptor and its potential role in breast cancer development. Journal of Pathology 188, 229-230.
Wark, J. D. (1996). Osteoporotic fractures: Background and prevention strategies. Maturitas 23, 193-207.
Watts, N. B. (1999). Postmenopausal Oteoporosis. Obstetrical and Gynecological Survey 54, 532-538.
Weaver, C. M. (2000). Calcium and magnesium requirements of children and adolescents and peak bone mass. Nutrition 16, 514-516.
Weaver, C. M., Peacock, M., and Johnson, C. C. (1999). Adolescent nutrition in the prevention of postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 84, 1839-1843.
Willett, W. C., Colditz, G., and Stampfer, M. (2000). Postmenopausal estrogens-opposed, unopposed, or none of the above. Journal of the American Medical Association 283, 534-535.
Williams, C. L., and Stancel, G. M. (1996). Estrogens and progestins. In The Pharmacological Basis of Therapeutics, J. G. Hardman, and L. E. Limbird, eds. (New York, McGraw-Hill).
Wiseman, H. (2000). The therapeutic potential of phytoestrogens. Expert Opinions on Investigational Drugs 9, 1829-1840.
Wood, R. J., and Fleet, J. C. (1998). The genetics of osteoporosis: Vitamin D receptor polymorphisms. Annual Review Nutrition 18, 233-258.
Wren, B. G. (1998). Megatrials of hormonal replacement therapy. Drugs and Aging 12, 243-348.
Youngs, D. D. (1990). Some misconceptions concerning the menopause. Obstetrics and Gynecology 75, 881-883.
Zumoff, B. (1998). Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy. Proceedings of the Society for Experimental Biology and Medicine 217, 30-37.
Beresford, S. A. A., Weiss, N. S., Voight, L. F., and McKnight, B. (1997). Risk of endometrial cancer in relation to use of oestrogen with cyclic progestagen therapy in postmenopausal women. Lancet 349, 458-461.
Castelo-Branco, C., Figueras, F., Sanjuan, A., Vicente, J. J., Martinez de Osaba, M. J., Pons, F., Balasch, J., and Vanrell, J. A. (1999). Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause 6, 307-311.
Mulnard, R. A., Cotman, C. W., Kawas, C., van Dyck, C. H., Sano, M., Doody, R., Koss, E., Pfeiffer, E., Jin, S., Gamst, A., et al. (2000). Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. Journal of the American Medical Association 283, 1007-1015.
Ravn, P., Bidstrup, M., Wasnich, R. D., Davis, J. W., McClung, M. R., Balske, A., Coupland, C., Sahota, O., Kaur, A., Daley, M., and Cizza, G. (1999). Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Annals of Internal Medicine 131, 935-942.
Reame, N. E., Kelch, R. P., Beitins, I. Z., Yu, M., Zawacki, C. M., and Panmanabhan, V. (1996). Age effects of follicle-stimulanting hormone and pulsatile luteinizing hormone secretion across the menstrual cycle of premenopausal women. Journal of Clinical Endocrinology & Metabolism 81, 1512-1518.
Yaffe, K., Sawaya, G., Lieberburg, I., and Grady, D. (1998). Estrogen therapy in postmenopausal women:effects on cognitive function and dementia. Journal of American Medical Association 279, 688-695.
Young, D., Hopper, J. L., Nowson, C. A., Green, R. M., Sherwin, A. J., Kaymakci, B., Smid, M., Guest, C. S., Larkins, R. G., and Wark, J. D. (1995). Determinants of bone mass in 10 to 26-year old females: A twin study. Journal of Bone Mineral Research 10, 558-567.
Beresford, S. A. A., Weiss, N. S., Voight, L. F., and McKnight, B. (1997). Risk of endometrial cancer in relation to use of oestrogen with cyclic progestagen therapy in postmenopausal women. Lancet 349, 458-461.
Bergkvist, L., Adami, H. O., Persson, I., Hoover, R., and Schairer, C. (1989). The risk of breast cancer after estrogen and estrogen progestin replacement. New England Journal of Medicine 321, 293-297.
Brinton, L. A., and Hoover, R. N. (1993). Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obsterics and Gynecology 81, 265-271.
Byrne, C., Connolly, J. L., Colditz, G. A., and Schnitt, S. J. (2000). Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Cancer 89, 2046-2052.
Colditz, G. A., Egan, K. M., and Stampfer, M. J. (1993). Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Obstetric Gynecology 168, 1473-1480.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., and Spiezer, F. D. (1995). The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New England Journal of Medicine 332, 1589-1593.
Collaborative Group on Hormonal Factors in Breast Cancer (1997). Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350, 1047-1059.
Coughlin, S. S., Giustoozzi, A., Smith, S. J., and Lee, N. C. (2000). A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. Journal of Clinical Epidemiology 53, 367-375.
Dennerstein, L., Dudley, E. C., Hopper, J. L., Guthrie, J. R., and Burger, H. G. (2000). A prospective population-based study of menopausal symptoms. Obstetrics and Gynecology 96, 351-358.
Garg, P. P., Kerlinkowski, K., Subak, L., and Grady, D. (1998). Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis. Obstetrics and Gynecology 92, 472-479.
Grady, D., Gebretsadik, T., Kerlikowski, K., Ernster, V., and Petitti, D. (1995). Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstertics and Gynecology 85, 304-313.
Guidozzi, F. (1999). Estrogen replacement therapy in breast cancer survivors. International Journal Gynaecology and Obstetrics 64, 59-63.
Hill, D. A., Weiss, N. S., Beresford, S. A., Voigt, L. F., Daling, J. R., Stanford, J. L., and Self, S. (2000). Continuous combined hormone replacement therapy and risk of endometrial cancer. American Journal Obstetrics and Gynecology 183, 1456-1461.
Hill, D. A., Weiss, N. S., Beresford, S. A., Voigt, L. F., Daling, J. R., Stanford, J. L., and Self, S. (2000). Continuous combined hormone replacement therapy and risk of endometrial cancer. American Journal of Obstertics and Gynecology 183, 1456-1461.
Jain, M. G., Rohan, T. E., and Howe, G. H. (2000). Hormone replacement therapy and endometrial cancer in Ontario, Canada. Journal of Clinical Epidemiology 53, 385-391.
Jick, S. S., Walker, A. M., and Jick, H. (1993). Estrogen, progesterone, and endometrial cancer. Epidemiology 4, 20-24.
Kato, I., Toniolo, P., Zeleniuch-Jacquotte, A., Shore, R. E., Koenig, K. L., Akhmedkahanov, A., and Riboli, E. (2000). Diet, smoking and anthropometric indices and postmenopausal bone fractures: A prospective study. International Journal of Epidemiology 29, 85-92.
Magnusson, C., Baron, J. A., Correia, N., Bergstrom, R., Adami, H.-O., and Persson, I. (1999). Breast cancer risk following long-term oestrogen- and oestrogen-pregestin-replacement therapy. International Journal of Cancer 81, 339-344.
Moerman, C. J., Van Hout, B. A., Bonneux, L., and Witteman, J. C. M. (2000). Postmenopausal hormone therapy: Less favourable risk-benefit ratios in healthy Dutch women. Journal of Internal Medicine 248, 143-150.
Panico, S., Galasso, R., Celentano, E., Ciadullo, A. V., Frova, L., Capocaccia, R., Trevisan, M., and Berriino, F. (2000). Large-scale hormone replacement therapy and life expectancy: Results from an international comparison European and North American populations. American Journal of Public Health 90, 1397-1402.
Pike, M. C., and Ross, R. K. (2000). Progestins and menopause: Epidemiological studies of risks of endometrial and breast cancer. Steroids 65, 659-664.
Pike, M. C., Peters, R. K., Cozen, W., Probst-Hensch, N. M., Felix, J. C., Wan, P. C., and Mack, T. M. (1997). Estrogen-progestin replacement therapy and endometrial cancer. Journal of the National Cancer institute 89, 1110-1116.
Ross, R. K., Paganini_Hill, A., Wan, P. C., and Pike, M. C. (2000). Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 92, 328-332.
Schairer, C., Byrne, C., Keyl, P. M., Brinton, L. A., Sturgeon, S. R., and Hoover, R. N. (1994). Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 5, 491-500.
Schairer, C., Lubin, J., Troisi, R., Sturgeon, S., Brinton, L., and Hoover, R. (2000). Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. Journal of the American Medical Association 283, 485-491.
Steinberg, K. K., Smith, S. J., Thacker, S. B., and Stroup, D. F. (1994). Breast cancer risk and duration of estrogen use: The role of study design in meta-analysis. Epidemiology 5, 415-421.
Steinberg, k. K., Thacker, S. B., Smith, S. J., Stroup, D. F., Zack, M. M., Flanders, W. D., and Berkelman, R. L. (1991). A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. Journal of the American Medical Association 265, 1985-1990.
Uhler, M. L., Marks, J. W., and Judd, H. L. (2000). Estrogen replacement therapy and gallbladder disease in postmenopausal women. Menopause 7, 162-167.
Vassilopoulou-Sellin, R., Asmar, L., Hortobagyi, G. N., Klein, M. J., McNeese, M., Singletary, S. E., and Theriault, R. L. (1999). Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively. Journal Clinical Oncology 17, 1482-1787.
Weiderpass, E., Adami, H.-O., Baron, J. A., Magnusson, C., Bergstrom, R., Lindgrem, A., Correia, N., and Persson, I. (1999). Risk of endometrial cancer following estrogen replacement with and without progestins. Journal of the National Cancer Institute 91, 1131-1137.
Review Articles and Commentaries
Barbieri, R. L., Speroff, L., Walker, A. M., and McPherson, K. (1999). The safety of third-generation oral contraceptives. Journal of Clinical Endocrinology & Metabolism 84, 1822-1829.
Burke, W. (2000). Oral contraceptives and breast cancer. Journal of American Medical Association 284, 1837-1839.
Castelli, W. P. (1999). Cardiovascular disease: pathogenesis, epidemiology, and the risk among users of oral contraceptives who smoke. American Journal of Obstetrics and Gynecology 180, S349-S356.
ESHRE Capri Workshop Group (1998). Hormones and cardiovascular diseases: Oral contraceptives and hormonal replacement therapy: differential effects on coronary heart disease, deep venous thrombosis and stroke. Human Reproduction 13, 2325-2333.
Furedi, A. (1999). The public health implications of the 1995 'pill scare'. Human Reproductive Update 5, 621-626.
Jensen, J. T., and Speroff, L. (2000). Health benefits of oral contraceptives. Obstetrics and Gynecology Clinics of North America 27, 705-721.
Kaper, R. F., Norpoth, T., and Rekers, H. (2000). Third- and second-generation oral contraceptives are associated with similar risk estimates for venous thromboembolism. European Journal of Contraception Reproduction Health Care 5, 1-15.
LeBlanc, E. S., and Laws, A. (1999). Benefits and risk of third-generation oral contraceptives. Journal of General Internal Medicine 14, 625-632.
Pike, M. C., and Spicer, D. V. (1993). Oral contraceptives and cancer. In Contraception, D. Shoupe, and F. Haseltine, eds. (Springer-Verlag), pp. 67-83.
Pike, M. C., and Spicer, D. V. (2000). Hormonal contraception and chemoprevention of female cancers. Endocrine-Related Cancer 7, 73-83.
Ursin, G., Li, C., and Pike, M. C. (2000). Should women with a family history of breast cancer avoid use of oral contraceptives. Epidemiology 11, 615-616.
Van Os, W. A. A., Edelman, D. A., Rhemrev, P. E. R., and Grant, S. (1997). Oral contraceptives and breast cancer risk. Advances in Contraception 13, 63-69.
Brinton, L. A., Daling, J. R., Liff, J. M., Schoenberg, J. B., Malone, K. E., Stanford, J. L., Coates, R. J., Gammon, M. D., Hanson, L., and Hoover, R. N. (1995). Oral contraceptives and breast cancer risk among younger women. Journal National Cancer Institute 87, 827-835.
Colditz, G. A., Rosner, B., and Speizer, F. E. (1996). Risk factors for breast cancer according to family history of breast cancer. Journal of the National Cancer Institute 88, 365-371.
Collaborative Group Hormonal Factors in Breast Cancer. (1996). Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347, 1713-1727.
Gambrell, R. D., Maier, R. C., and Sanders, B. I. (1983). Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstetrics and Gynecology 62, 435-443.
Grabrick, D. M., Hartmann, L. C., Cerhan, J. R., Vierkant, R. A., Therneau, T. M., Vachon, C. M., Olson, J. E., Couch, F. J., Anderson, K. E., Pankratz, V. S., and Sellers, T. A. (2000). Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. Journal of the American Medical Association 284, 1791-1798.
Grodstein, F., Colditz, G. A., Hunter, D. J., Manson, J. E., Willett, W. C., and Stampfer, M. J. (1994). A prospective study of symptomatic gallstones in women: relation with oral contraceptives and other risk factors. Obstetrics and Gynecology 84, 207-214.
Jick, S. S., Walker, A. M., Stergachis, A., and Jick, H. (1989). Oral contraceptives and breast cancer. British Journal of Cancer 59, 618-621.
Kay, C. R., and Hannaford, P. C. (1988). Breast cancer and the pill - A further report from the royal college of general practitioners' oral contraception study. British Journal of Cancer 58, 675-680.
Magnusson, C. M., Persson, I. R., Baron, J. A., Ekbom, A., Bergstrom, R., and Adami, H. (1999). The role of reproductive factors and use of oral contraceptives in the aeteology of breast cancer in women aged 50 to 74 years. International Journal of Cancer 80, 231-236.
Martinez, M. E., Grodstein, F., Giovannucci, E., Colditz, G. A., Speizer, F. E., Hennekens, C., Rosner, B., Willett, W. C., and Stampfer, M. J. (1997). A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiology Biomarkers and Prevention 6, 1-5.
McPherson, K., Vessey, M. P., Neil, A., Doll, R., Jones, L., and Roberts, M. (1987). Early oral contraceptive use and breast cancer: Results of another case-control study. British Journal of Cancer 56, 653-660.
Paul, C., Skegg, D. C. G., and Spears, G. F. S. (1990). Oral contraceptives and risk of breast cancer. International Journal of Cancer 46, 366-373.
Ravnihar, B., Primic Zakelj, M., Kosmelj, K., and Stare, J. (1988). A case-control study of breast cancer in relation to oral contraceptive use in Slovenia. Neoplasma 35, 109-121.
Rohan, T. E., and McMichael, A. J. (1988). Oral contraceptive agents and breast cancer: a population-based case-control study. The Medical Journal of Australia 149, 520-526.
Romieu, I., Willett, W. C., Colditz, G. A., Stampfer, M. J., Rosner, B., Hennekens, C. H., and Speizer, F. E. (1989). Prospective study of oral contraceptive use and risk of breast cancer in women. Journal of the National Cancer Institute 81, 1313-1321.
Rosenberg, L., Palmer, J. R., Clarke, E. A., and Shapiro, S. (1992). A case-control study of the risk of breast cancer in relation to oral contraceptive use. American Journal of Epidemiology 136, 1437-1443.
Rosenberg, L., Palmer, J. R., Rao, R. S., Zauber, A. G., Strom, B. L., Warshauer, M. E., Harlap, S., and Shapiro, S. (1996). Case-control study of oral contraceptive use and risk of breast cancer. American Journal of Epidemiology 143, 25-37.
Rosner, D., Lane, W. W., and Perez Brett, R. (1985). Influence of oral contraceptives on the prognosis of breast cancer in young women. Cancer 55, 1556-1562.
Sauerbrei, W., Blettner, M., Schmoor, C., Bojar, H., and Schumacher, M. (1998). The effect of oral contraceptive use on the prognosis of node positive breast cancer patients. European Journal of Cancer 34, 1348-1351.
Schildkraut, J. K., Hulka, B. S., and Wilkinson, W. E. (1990). Oral contraceptives and breast cancer: A case-control study with hospital and community controls. Obstetrics and Gynecology 76, 395-401.
Thijs, C., and Knipschild, P. (1993). Oral contraceptives and the risk of gallbladder disease: A meta-analysis. American Journal of Public Health, 1113-1120.
Ursin, G., Henderson, B. E., Haile, R. W., Pike, M. C., Zhou, N., Diep, A., and Bernstein, L. (1997). Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Research 57, 3678-3681.
Ursin, G., Ross, R. K., Sullivan-Halley, J., Hanisch, R., Henderson, B., and Bernstein, L. (1998). Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Research and Treatment 50, 175-184.
Ursin, G., Wu, A. H., Hoover, R. N., West, D. W., Nomura, A. M., Kolonel, L. N., Pike, M. C., and Ziegler, R. G. (1999). Breast cancer and oral contraceptive use in Asian-American women. American Journal of Epidemiology 150, 561-567.
Van Hoften, C., Burger, H., Peeters, P. H. M., Grobbee, D. E., and Van Noord, P. A. H. (2000). Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the dom cohort. International Journal of Cancer 87, 591-594.
Vessey, M. P., McPherson, K., Villard-Mackintosh, L., and Yeates, D. (1989). Oral contraceptives and breast cancer: Latest findings in a large cohort study. British Journal of Cancer 59, 613-617.
Prepared by Barbour S. Warren, Ph.D., Research Associate., BCERF.
We will make every effort to update this bibliography. If you have comments on this bibliography, or have a suggestion of a reference you would like us to review for inclusion in the bibliography, please send this information via email to: breastcancer@cornell.edu
Program on Breast Cancer and Environmental Risk Factors
Cornell University, College of Veterinary Medicine
Vet Box 31, Ithaca, NY 14853-6401
Phone: 607.254.2893; Fax: 607.254.4730
Email: breastcancer@cornell.edu
We comply with the HONcode standard for
trustworthy health information: Verify here.